GHP Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

GHP Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.7K	Buy	1,201 +1	+0.1%	+$24	﹤0.01%	640
2025 Q4	$28K	Hold	1,200	–	–	﹤0.01%	599
2025 Q3	$23.6K	Hold	1,200	–	–	﹤0.01%	609
2025 Q2	$26K	Hold	1,200	–	–	﹤0.01%	593
2025 Q1	$29.1K	Hold	1,200	–	–	﹤0.01%	558
2024 Q4	$25K	Hold	1,200	–	–	﹤0.01%	572
2024 Q3	$23.9K	Hold	1,200	–	–	﹤0.01%	597
2024 Q2	$18.6K	Hold	1,200	–	–	﹤0.01%	606
2024 Q1	$19.1K	Hold	1,200	–	–	﹤0.01%	594
2023 Q4	$20.2K	Hold	1,200	–	–	﹤0.01%	572
2023 Q3	$15.3K	Hold	1,200	–	–	﹤0.01%	641
2023 Q2	$17.9K	Hold	1,200	–	–	﹤0.01%	602
2023 Q1	$19.9K	Hold	1,200	–	–	﹤0.01%	585
2022 Q4	$22.3K	Hold	1,200	–	–	﹤0.01%	567
2022 Q3	$15K	Hold	1,200	–	–	﹤0.01%	611
2022 Q2	$8K	Hold	1,200	–	–	﹤0.01%	717
2022 Q1	$10K	Buy	+1,200	New	+$8.48K	﹤0.01%	713

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GHP Investment Advisors's CPRX Position: Q1 2026 in Review

GHP Investment Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 0.08% in Q1 2026, buying an estimated $24 and bringing the position to 1,201 shares worth $29.7K. The position accounts for ﹤0.01% of the portfolio, ranked #640.

GHP Investment Advisors first reported a position in CPRX in Q1 2022 and has held it in 17 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

GHP Investment Advisors held 1,201 shares of Catalyst Pharmaceutical worth $29.7K as of Q1 2026.
GHP Investment Advisors bought 1 Catalyst Pharmaceutical share in Q1 2026, an estimated $24.
Catalyst Pharmaceutical made up ﹤0.01% of GHP Investment Advisors's portfolio in Q1 2026, its #640 holding.
GHP Investment Advisors first reported a position in Catalyst Pharmaceutical in Q1 2022 and has held it in 17 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on GHP Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.